Adrenomedullin hormone contributes to insulin resistance in obesity-associated type 2 diabetes
February 6, 2025 / Adrenomedullin / Insulin Resistance / Obesity / Type 2 Diabetes
Adrenomedullin disrupts insulin signaling in endothelial cells, contributing to insulin resistance in obesity-related type 2 diabetes. Blocking its effects improves glucose control in mice, suggesting a potential therapeutic target for obesity-related metabolic dysfunction.
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
February 5, 2025 / Novo Nordisk / CB1 Receptor / Obesity Treatment / Diabetic Kidney Disease Drug Failure
Novo Nordisk’s CB1-targeting drug, monlunabant, failed a Phase 2b trial for diabetic kidney disease and showed mild-to-moderate neuropsychiatric side effects. Despite prior weight-loss efficacy, safety concerns may impact its obesity development strategy. Competitors pursue peripherally restricted CB1 therapies.
Study Finds 3 in 4 Overweight, Obese Adults Have Steatotic Liver Disease MASH
February 11, 2025 / Steatotic Liver Disease in Obesity / MASLD Prevalence in Overweight Adults / Liver Fibrosis / Metabolic Syndrome
A study found that 75% of overweight and obese adults have steatotic liver disease (SLD), with 67.3% having MASLD. Advanced fibrosis was linked to metabolic syndrome, diabetes, and obesity, supporting earlier screening and personalized liver disease management strategies.
Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments
February 10, 2025 / Revita Endoscopic Weight Maintenance / GLP-1 Treatment / Fractyl Health / Rejuva Gene Therapy / Diabetes
Fractyl Health is developing Revita, an FDA-designated endoscopic procedure to maintain weight loss after GLP-1 discontinuation, and Rejuva, a gene therapy for Type 2 diabetes. Both aim to provide long-term metabolic disease solutions beyond traditional GLP-1 treatments.
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
February 6, 2024 / RDX-002 Post GLP-1 Weight Management / Obesity Treatment / Semaglutide / Tirzepatide / Cardiometabolic Risk
Response Pharmaceuticals completed early enrollment for a Phase 2 trial of RDX-002, an iMTP inhibitor aimed at preventing post-GLP-1 weight rebound. The study assesses its impact on triglycerides, body weight, and cardiometabolic risk factors in patients discontinuing semaglutide or tirzepatide.
Kidney-Protection Benefits of Metabolic Surgery Versus GLP1-RA in Patients With CKD
February 5, 2025 / Metabolic Surgery / CKD Treatment / Obesity / Chronic Kidney Disease Management / Metabolic Surgery
In patients with CKD, obesity, and type 2 diabetes, metabolic surgery reduced the risk of kidney disease progression by 60% and kidney failure or death by 44% compared to GLP-1RA therapy, highlighting its superior renoprotective benefits over 8 years.
Effect of gold nanoparticles treatment on rats-induced obesity by evaluating body-composition directly and indirectly via bioelectric impedance analysis
February 10, 2025 / Gold Nanoparticles / Obesity Treatment / AuNPs vs. Orlistat Weight Loss / Liver and Kidney Repair / Bioelectric Impedance Obesity Analysis
In an obesity-induced rat model, gold nanoparticles (AuNPs) outperformed orlistat, reducing body fat, improving lipid and glucose metabolism, and repairing liver and kidney damage. AuNPs showed antioxidant effects, suggesting a potential novel obesity treatment.
Gene Discovery Sheds Light on Obesity’s Impact and Potential Treatments
February 10, 2025 / University of Delaware / Obesity Gene Expression Research / Targeted Obesity Treatments / Inflammation Pathways
University of Delaware researchers identified obesity-related gene expression differences in visceral and subcutaneous fat, highlighting metabolism, calcium handling, and inflammation pathways. These findings may lead to targeted obesity treatments and inform personalized interventions based on sex differences in adipose function.
Your gut bacteria shape your health from childhood to old age, study reveals
February 10, 2025 / Gut Microbiome / Metabolic Health / Obesity / Metabolic Interventions / Cardiovascular Risk / Gut Health
A Dutch study linked gut microbiome composition to metabolic health across life stages, identifying unhealthy microbiome profiles associated with obesity, insulin resistance, and cardiovascular risk. Findings suggest gut-targeted interventions could help prevent metabolic disorders but require further research.
New method revolutionizes body composition analysis using 3D imaging and deep learning
February 4, 2024 / 3D Imaging for Body Composition / Deep Learning / Health Assessments / Obesity / Muscle Distribution Analysis / AI-Driven Body Fat Measurement
Researchers developed a 3D imaging and deep learning method to improve body composition analysis, providing more accurate assessments of fat and muscle distribution. This breakthrough enhances clinical evaluations of obesity, cardiovascular risk, and metabolic disorders.
Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity
February 4, 2025 / Metabolic Surgery / MASH Cirrhosis / Obesity Treatment / Liver Disease Treatment / Major Adverse Liver Outcomes (MALO) Risk / Bariatric Surgery
A study in Nature Medicine found that metabolic surgery significantly reduces the risk of major adverse liver outcomes (MALO) and decompensated cirrhosis in patients with MASH-related cirrhosis and obesity, suggesting it as a viable therapeutic option.
Swiss study sheds light on link between obesity and metabolic diseases
February 5, 2025 / Obesity and Metabolic Disease Risk / Cellular Changes in Overweight Individuals / Visceral Fat / Metabolic Health / Diabetes / Hypertension
Swiss researchers mapped cellular changes in obesity, identifying biomarkers that predict metabolic disease risk. They also found sex-specific differences in visceral fat cells, which may explain variations in disease development between men and women.
Study Reveals Low Metabolic Syndrome Rates Among HIV Patients
February 8, 2025 / HIV and Metabolic Syndrome Risk / Integrase Inhibitors / Metabolic Health / Againg and Metabolic Syndrome / HAART Therapy
A Taiwanese study found a low metabolic syndrome prevalence (10%) among HIV patients, possibly due to integrase inhibitors in antiretroviral therapy. Aging, rather than HIV-related factors, was the strongest risk factor, highlighting the need for preventative metabolic care.
Addressing metabolic issues with a culturally safe healthcare model for Aboriginal people
February 9, 2025 / Culturally Safe / Obesity Care / Aboriginal Metabolic Health Program / Australia / Holistic Obesity Treatment
A culturally adapted metabolic health program for Aboriginal people in South Western Sydney integrates medical, dietary, and lifestyle interventions within a culturally safe environment. Early results show improved engagement, metabolic health, and social well-being among participants.
Effects of monitoring dietary biomarkers and providing vegetable juice on metabolic syndrome components in adults with an overweight or obese body mass index in Ulaanbaatar: a randomized controlled trial
February 10, 2025 / Vegetable Juice / Metabolic Syndrome / Dietary Biomarkers for Obesity / Metabolic Health / Obesity
A randomized trial in Mongolia found that monitoring dietary biomarkers and providing vegetable juice improved waist circumference, skin carotenoid levels, and sodium-to-potassium ratio, suggesting a diet-based intervention for metabolic syndrome in overweight and obese adults.
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes
February 10, 2025 / GLP-1 Agonists / MASLD Treatment / Metabolic Liver Disease / Cardiovascular Risk / Portal Hypertension / MASLD Patients
A large cohort study found that GLP-1 receptor agonists significantly reduce cardiovascular events, portal hypertension, and mortality in MASLD patients over seven years. These findings highlight GLP-1 therapy’s potential in metabolic liver disease management.
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
February 10, 2025 / OliX Lilly RNAi Partnershi[p / MASH Treatment / OLX75016 / RNAi Therapy / Liver Fibrosis / Cardiometabolic Disease Drug Development
OliX Pharmaceuticals and Eli Lilly entered a global licensing agreement for OLX75016, an RNAi therapeutic in Phase 1 trials for MASH and cardiometabolic diseases. The collaboration aims to advance novel metabolic treatments targeting liver fibrosis and metabolic dysfunction.
Study Finds 3 in 4 Overweight, Obese Adults Have Steatotic Liver Disease MASH
February 11, 2024 / Obesity / Liver Disease Risk / MASLD Prevalence / Metabolic Syndrome
A study found 75% of overweight and obese adults have steatotic liver disease (SLD), with 67.3% diagnosed with MASLD. Advanced fibrosis and cirrhosis were linked to metabolic syndrome and diabetes, highlighting the need for early screening and targeted interventions.
The Hidden Link Between Stress, Weight Gain and High Blood Pressure—And How to Fix It
February 1, 2024 / Stress / Metabolic Syndrome / Hypertension / Chronic Stress / Blood Pressure Control / Metabolic Health
Chronic stress contributes to metabolic syndrome, increasing the risk of hypertension, weight gain, and high blood sugar. Research suggests meditation, interval walking, and cold therapy can help regulate stress, lower inflammation, and improve metabolic health without medical intervention.